期刊文献+

卵巢交界性上皮性肿瘤58例临床分析 被引量:5

The Clinical Analysis of 58 Cases with Borderline Ovarian Tumors
暂未订购
导出
摘要 目的:探讨卵巢交界性上皮性肿瘤(BOT)的临床情况及影响复发的有关因素。方法:回顾性分析我院诊治的58例BOT患者的临床资料及治疗结局。结果:58例患者的平均发病年龄为37.6岁;临床表现以无症状的盆腔肿块为主,共29例占50.00%;血清肿瘤标志物:CA125升高33例(56.90%),CA199升高20例(34.48%),两者比较差异有统计学意义(P<0.05)。所有患者均进行手术治疗,其中37例患者行保留生育功能手术。分期以Ⅰ期最多,占87.93%;浆液性和黏液性分别为25例和33例。术后随访8~68月,患者均存活;4例(6.90%)复发,肿瘤有微乳头或浸润性种植的患者复发率较高(P<0.05)。5例保留生育功能手术的患者在手术后正常妊娠并分娩。结论:BOT患者较年轻,以Ⅰ期为主,血CA125检测对诊断有帮助。手术是主要治疗手段,患者预后较好。其复发与肿瘤存在微乳头或浸润性种植可能有关。对其进行保留生育功能手术是安全有效的,术后需长期随访。 Objective:To evaluate the clinical features of borderline ovarian tumors (BOT) and to develop the potential prognostic factors of BOT. Methods:The clinical data of 58 patients with BOTS who were diag- nosed and treated in our hospital were retrospectively analyzed. Results:The mean age of BOT patients was 37.6 years. The main clinical feature of BOT is the symptomless pelvic cavity mass,which was found in 29 cases(50.00% of the cases). 33 cases(56.90% ) had a raised blood CA12s level,and 20 cases(34. 48% raised in blood CA199 level( P 〈 0.05). All patients underwent surgery as the initial treatment, of whom 37 ca- ses underwent conservative surgery. Most of them were in FIGO stage | (87.93%). Duration of foUow-up was 8 ~68 months. 4 cases (6.90%) developed a recurrence. The recurrence rate of micro-papillary carci- noma or micro-invasive carcinoma cases were higher than others( P 〈 0. 05). Five patients underwent con- servative surgery had normal spontaneous delivery after normal pregnancy. Conclusions.. The clinical fea- tures of the borderline ovarian tumors is that most cases are young women,in FIGO stage I. CA12S can help to establish a diagnosis of BOT. Surgery is the main treatment of BOT,and patients have favorable prognosis after surgery. The recurrence of BOT may be related to micro-papillary carcinoma or micro-invasive carcino- ma. Conservative surgery is proved an effective and safe treatment for borderline ovarian tumors, and Iona-term follow-up is required.
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2013年第10期765-768,共4页 Journal of Practical Obstetrics and Gynecology
关键词 卵巢交界性肿瘤 癌抗原125 手术病理分期 复发 Borderline ovarian tumors CA12s Surgical pathological staging Recurrence
  • 相关文献

参考文献13

  • 1Berman JJ. Borderline ovarian tumor workshop, bethesda, maryland, 2003 [ J ]. Hum Patho1,2004,35 ( 8 ) :907 - 909.
  • 2Ha JE. Clinical analysis of borderline ovarian tumors[ J]. Eur J Gynae- col Oncol,2011,32( 1 ) :69 -72.
  • 3曹冬焱,沈铿,陶陶,杨佳欣,向阳,黄惠芳,吴鸣,潘凌亚,郎景和.卵巢交界性黏液性肿瘤130例临床病理分析[J].中华妇产科杂志,2011,46(1):15-18. 被引量:10
  • 4Somsukolrat S,Tuipae S. Prognostic factors and survival of borderline ovarian tumors in rajavithi hospital between 1979 2006 AD [ J]. J Med Assoc Thai, 2012,95 ( 9 ) : 1141 - 1148.
  • 5Messalli EM, Grauso F. Borderline ovarian tumors:features and con- troversial aspects [ J]. Eur J Obstet Gyneeol Reprod Biol,2013,167 (1) :86 -89.
  • 6Vaisbueh E,Dgani R,Ben-Arie A,et al. The role of laparoseopy in o- varian tumors of low malignant potential and early-stage ovarian canc- er[ J ]. Obstet Gynecol Surv ,2005,60 (5) 326 - 330.
  • 7Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malig- nant potential( serous borderline tumors). A long2term follow-up stud- y,including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma [ J]. Cancer, 1996,78 (2) :278 -286.
  • 8Rao GG, Skinner E, Gehrig PA, et al. Surgical staging of ovarian low malignant potential tumors [ J ]. Obstet Gynecol, 2004, 104 ( 2 ) : 261 - 266.
  • 9Moriee P, Camatte S, Wieart PF, et al. Results of conservative manage- ment of epithelial malignant and borderline epithelial ovarian tumor [ J ]. Hum Reprod Update,2003,9 ( 2 ) : 1852 - 1892.
  • 10Faluyi O. Interventions for the treatment of borderline ovarian tumours [ J ]. Coehrane Database Syst Rev, 2010,8 ( 9 ) : CD007696.

二级参考文献12

  • 1邵汇琳,沈丹华,薛卫成,李艺,虞有智.卵巢上皮性肿瘤的临床病理特征及其细胞周期素D1和p53蛋白表达的研究[J].中华妇产科杂志,2007,42(4):227-232. 被引量:10
  • 2Tropé CG,Kristensen G,Makar A.Surgery for borderline tumor of the ovary.Semin Surg Oncol,2000,19:69-75.
  • 3Scully RE,Bell DA,Abu-Jawdeh GM.Update on early ovarian cancer and cancer developing in benign ovarian tumours//Sharp F,Mason P,Blackett T,eds.Ovarian Cancer 3.London:Chapman & Hall Medical,1995:139-144.
  • 4Scully RE.International histological classification and staging of tumors:histological typing of ovarian tumors.Geneva:World Health Organization,1999:12-15.
  • 5Changes in definitions of clinical staging for carcinoma of the cervix and ovary:International Federation of Gynecology and Obstetrics.Am J Obstet Gynecol,1987,156:263-264.
  • 6Faluyi O,Mackean M,Gourley C,et al.Interventions for the treatment of borderline ovarian tumours.Cochrane Database Syst Rev,2010,9:CD007696.
  • 7Kurman RJ,Visvanathan K,Roden R,et al.Early detection and treatment of ovarian cancer:shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.Am J Obstet Gynecol,2008,198:351-356.
  • 8Gusberg SB,Deligdisch L.Ovarian dysplasia.A study of identical twins.Cancer,1984,54:1-4.
  • 9Plaxe SC,Deligdisch L,Dottino PR,et al.Ovarianintraepithelial neoplasia demonstrated in patients with stage Ⅰ ovarian carcinoma.Gynecol Oncol,1990,38:367-372.
  • 10Riopel MA,Ronnett BM,Kurman BJ.Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors:atypical proliferative (borderline) tumors and intraepithelial,microinvasive,invasive,and metastatic carcinomas.Am J Surg Pathol,1999,23:617 -635.

共引文献9

同被引文献48

  • 1Lax S, Staebler A. Mucinous ovarian neoplasms. Prognosti- cally mostly excellent, infrequently a wolf in sheep ~s cloth- ing[ J]. Pathologe ,2014,35 (4) :327-335.
  • 2Ledermann JA,Luvero D, Shafer A, et al. Gynecologic Can- cer InterGroup (GCIG) consensus review for mucinous o- varian carcinoma [ J 1. Int J Gynecol Cancer, 2014,24 ( 9 Suppl 3 ) : S14-19.
  • 3P JG, R VC, P KM, et al. Primary ovarian mucinous carci- noma with signet ring cells-report of a rare case[ J]. J Clin Diagn Res,2014,8(6) :FD12-13.
  • 4Mikami Y. Paradigm shift in ovarian tumor pathology from the view ofgenomic abnormalities [J]. Gan To Kagaku Ryoho, 2016,43(3) :286-289.
  • 5孙但窈.卵巢交界性肿瘤病理及影响预后相关因素分析[D],乌鲁木齐:新疆医科大学.2015.
  • 6Hashmi AA, Hussain ZF,Bhagwani AR,et al. Clinico- pathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors:an institutional perspective [J]. BMC Res Notes, 2016,9(1) : 205.
  • 7Li X, Yang J,Wang X, et al. Role of TWIST2, E -cad- herin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression [J]. Eur J Gynaecol Oncol, 2016,37(1 ) : 100-108.
  • 8Tiwari RK, Saha K, Mukhopadhyay D, et al. Evaluation of preoperative serum levels of CA125 and Expression of p53 in ovarian neoplasms:a prospective clinicopathologi- cal study in a Tertiary Care Hospital [J]. J Obstet Gynaeeol India, 2016,66(2) : 107-114.
  • 9Yoshida A, Derchain SF,Pitta DR,et al. Comparing the Copenhagen Index (CPH-I)and Risk of Ovarian Malig- nancy Algorithm(ROMA) :two equivalent ways to differ- entiate malignant from benign ovarian tumors before surgery? [J]. Gynecol Oncol,2016,140(3) :481-485.
  • 10Faluyi O,Mackean M,Gourley C,et al. Interventions for the treatmentof borderline ovarian tumours[J]. Cochrane Database Syst Rev,2010,2010(9):CD007696. doi:10.1002/14651858.CD007696.pub2.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部